Sign In
Buy QURE
$46.06
-0.360 (-0.776%)
At Close: Aug 10, 2026
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
03:20pm, Friday, 19'th Jun 2026
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~
UniQure: AMT-130's FDA Path Reaffirms My Bull Case
10:06am, Thursday, 18'th Jun 2026
QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-term BLA path for AMT-130. The main bet is that AMT-130 could eventually become the first approved dis
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
08:31am, Thursday, 18'th Jun 2026
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring
03:40pm, Wednesday, 17'th Jun 2026
uniQure N.V. surges as the FDA now accepts Phase 1/2 data for AMT-130 as the primary basis for accelerated approval in Huntington's disease. QURE plans to submit its BLA for AMT-130 in Q3 2026, with a
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
02:12pm, Wednesday, 17'th Jun 2026
Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
12:12pm, Wednesday, 17'th Jun 2026
UniQure said it plans to seek approval for its experimental gene therapy for Huntington's disease. The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over
What made uniQure stock nearly double on Wednesday?
11:32am, Wednesday, 17'th Jun 2026
uniQure (QURE) stock is ripping higher this morning after the biopharmaceutical firm announced a major regulatory breakthrough with the FDA for its Huntington's disease gene therapy AMT-130. As invest
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
10:31am, Wednesday, 17'th Jun 2026
uniQure N.V. (NASDAQ:QURE) stock is up during Wednesday's premarket session as the company announced plans for a Biologics License Application (BLA) submission for AMT-130, a gene therapy treatment fo
This Biotech Stock Is Surging 66% on Surprise Good News From FDA
10:10am, Wednesday, 17'th Jun 2026
Gene therapy maker uniQure is one step closer to marketing its treatment for Huntington's disease.
UniQure gets FDA green light to file for Huntington's gene therapy approval
07:13am, Wednesday, 17'th Jun 2026
Dutch drugmaker UniQure said on Wednesday the U.S. Food and Drug Administration has agreed that data from a mid-stage study could support an accelerated approval filin
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease
07:05am, Wednesday, 17'th Jun 2026
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~
uniQure: Why A Shifting FDA Could Change Everything For AMT-130
11:14am, Monday, 01'st Jun 2026
uniQure remains highly sensitive to AMT-130's regulatory outcome, with current valuation reflecting significant uncertainty around FDA approval. Recent FDA leadership changes and a scheduled Type B me
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play
10:24am, Tuesday, 12'th May 2026
UniQure is upgraded from Hold to Buy, driven by near-term UK approval prospects for AMT-130 and a robust cash runway to 2029. Despite FDA requiring a new Phase 3 trial for AMT-130 in Huntington's, a U
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
03:41pm, Tuesday, 05'th May 2026
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
